VERA
Bearish signalScored 2026-09-21 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Vera Therapeutics, Inc.
- Nom
- Vera Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.0B
- Employés
- 361
- PDG
- Marshall Fordyce
- Site web
- https://veratx.com
- Marché
- ACRSALMSANABARQTBHVNDNTH
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 37 000 titres (~1 334 142,30 $ US)
- Insiders
- Fordyce Marshall
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,334,142
Avg sell (VWAP, 90d window) $36.06 vs last close $33.05 (-8.3%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$1,334,142 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-15
- Liquidity
- Liquid $88,442,478/day · 20d vol
- Last synced
-
2026-09-23 21:11:09
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-15 | Fordyce Marshall | Sell · S · 10b5-1 | 18,500 | $37.00 | $684,500 | Form 4 |
| 2026-09-02 | Fordyce Marshall | Sell · S · 10b5-1 | 18,500 | $35.12 | $649,642 | Form 4 |
| 2026-06-23 | Fordyce Marshall | Sell · S · 10b5-1 | 88 | $38.43 | $3,382 | Form 4 |
| 2026-05-12 | Fordyce Marshall | Sell · S · 10b5-1 | 4,281 | $37.09 | $158,769 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-21 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $1.3M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $1.3M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 13.64 · operating margin 0.0%
Suggested stop 30.25, nearest stored support minus 0.5 ATR(8.5% under the last close). Reward/risk to the next stored resistance is 0.36. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 13.635 | 25.668 | 7.713 | 4.910 | 10.733 | |
| Quick Ratio | 13.635 | 25.668 | 7.713 | 4.910 | 10.733 | |
| Solvency Ratio | -2.297 | -1.936 | -1.299 | -1.649 | -2.291 | |
| Cash Ratio | 6.636 | 3.652 | 2.048 | 1.698 | 10.361 | |
| Price To Earnings Ratio | -10.867 | -15.378 | -6.836 | -5.776 | -10.996 | |
| Price To Earnings Growth Ratio | -0.156 | -0.692 | 0.208 | -0.153 | 0.132 | |
| Forward Price To Earnings Growth Ratio | -0.156 | -0.692 | 0.208 | -0.153 | 0.132 | |
| Price To Earnings Diluted Ratio | -10.867 | -15.378 | -6.836 | -5.776 | -10.996 | |
| Price To Earnings Diluted Growth Ratio | -0.156 | -0.692 | 0.208 | -0.153 | 0.132 | |
| Price To Book Ratio | 5.381 | 4.054 | 6.460 | 6.685 | 5.159 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -13.456 | -17.248 | -7.121 | -7.599 | -15.143 | |
| Price To Operating Cash Flow Ratio | -13.491 | -17.373 | -7.125 | -7.606 | -15.143 | |
| Debt To Assets Ratio | 0.105 | 0.083 | 0.306 | 0.238 | 0.059 | |
| Debt To Equity Ratio | 0.128 | 0.095 | 0.528 | 0.407 | 0.071 | |
| Debt To Capital Ratio | 0.113 | 0.086 | 0.346 | 0.289 | 0.066 | |
| Long Term Debt To Capital Ratio | 0.110 | 0.081 | 0.329 | 0.244 | 0.066 | |
| Financial Leverage Ratio | 1.215 | 1.136 | 1.726 | 1.709 | 1.203 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.510 | -5.308 | -4.133 | -2.640 | -3.083 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.007 | 1.001 | 1.001 | 1.000 | |
| Debt Service Coverage Ratio | -38.722 | -18.937 | -24.348 | -89.627 | -1,620.650 | |
| Interest Coverage Ratio | -41.890 | -21.921 | -26.945 | -91.636 | -1,720.100 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.119 | -2.465 | -1.716 | -2.161 | -4.816 | |
| Capital Expenditure Coverage Ratio | -382.705 | -138.559 | -1,463.190 | -1,090.258 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -382.705 | -138.559 | -1,463.190 | -1,090.258 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -10.203 | -15.938 | -7.212 | -5.646 | -8.770 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 13.636 | ▼-12.032 | ▲1.104 |
| Quick Ratio | 13.636 | ▼-12.032 | ▲1.104 |
| Solvency Ratio | -2.297 | ▼-0.361 | ▼-0.403 |
| Cash Ratio | 6.636 | ▲2.984 | ▲1.757 |
| Price To Earnings Ratio | -10.867 | ▲4.511 | ▼-0.896 |
| Price To Earnings Growth Ratio | -0.157 | ▲0.536 | ▼-0.024 |
| Forward Price To Earnings Growth Ratio | -0.157 | ▲0.536 | ▼-0.024 |
| Price To Earnings Diluted Ratio | -10.867 | ▲4.511 | ▼-0.896 |
| Price To Earnings Diluted Growth Ratio | -0.157 | ▲0.536 | ▼-0.024 |
| Price To Book Ratio | 5.381 | ▲1.327 | ▼-0.167 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -13.456 | ▲3.792 | ▼-1.343 |
| Price To Operating Cash Flow Ratio | -13.491 | ▲3.882 | ▼-1.344 |
| Debt To Assets Ratio | 0.105 | ▲0.022 | ▼-0.053 |
| Debt To Equity Ratio | 0.128 | ▲0.033 | ▼-0.118 |
| Debt To Capital Ratio | 0.113 | ▲0.027 | ▼-0.067 |
| Long Term Debt To Capital Ratio | 0.110 | ▲0.029 | ▼-0.056 |
| Financial Leverage Ratio | 1.215 | ▲0.079 | ▼-0.183 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.510 | ▲0.798 | ▼-0.575 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▼-0.005 | ▲0.000 |
| Debt Service Coverage Ratio | -38.722 | ▼-19.785 | ▲319.735 |
| Interest Coverage Ratio | -41.890 | ▼-19.969 | ▲338.608 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -3.119 | ▼-0.654 | ▼-0.264 |
| Capital Expenditure Coverage Ratio | -382.705 | ▼-244.146 | ▲232.238 |
| Dividend Paid And Capex Coverage Ratio | -382.705 | ▼-244.146 | ▲232.238 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -10.203 | ▲5.735 | ▼-0.649 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.25B | $2.34B | $656.8M | $514.1M | $359.0M | |
| Enterprise value | $2.98B | $2.30B | $664.9M | $502.0M | $284.3M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -12.34x | -17.09x | -7.21x | -7.43x | -11.99x | |
| EV / Free cash flow | -12.31x | -16.97x | -7.21x | -7.42x | -11.99x | |
| EV / EBITDA | -10.20x | -15.94x | -7.21x | -5.65x | -8.77x | |
| Net debt / EBITDA | 0.95x | 0.26x | -0.09x | 0.14x | 2.31x | |
| Current ratio | 13.63x | 25.67x | 7.71x | 4.91x | 10.73x | |
| Income quality | 0.81x | 0.89x | 0.96x | 0.76x | 0.73x | |
| Graham net-net | $9 | $10 | $2 | $2 | $5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 102.6% | 105.3% | 104.1% | 101.1% | 100.1% | |
| Working capital | $675.4M | $625.8M | $149.7M | $100.1M | $74.8M | |
| Invested capital | $677.4M | $630.2M | $152.8M | $105.3M | $74.8M | |
| Return on assets | -40.8% | -23.2% | -54.7% | -67.8% | -38.9% | |
| Operating ROA | -45.4% | -40.2% | -66.5% | -84.5% | -49.7% | |
| Return on tangible assets | -40.8% | -23.2% | -54.7% | -67.8% | -38.9% | |
| Return on equity | -49.6% | -26.4% | -94.4% | -115.8% | -46.9% | |
| Return on invested capital | -46.3% | -26.5% | -65.5% | -83.8% | -45.2% | |
| Return on capital employed | -46.3% | -26.5% | -66.6% | -85.9% | -45.2% | |
| Earnings yield | -9.2% | -6.5% | -14.6% | -17.3% | -9.1% | |
| Free cash flow yield | -7.4% | -5.8% | -14.0% | -13.2% | -6.6% | |
| Capex / Op. cash flow | -0.3% | -0.7% | -0.1% | -0.1% | 0.0% | |
| Capex / Depreciation | 134.6% | 925.7% | -1.5% | -7.3% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | -5173d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 5173d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-15 Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-15 What''s Going on With Vera Therapeutics Stock on Tuesday? Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.
- 2026-09-15 Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
- 2026-09-15 Why is Vera Therapeutics stock reversing its premarket gains? Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (atacicept-vymj) met all primary and secondary endpoints in the final 104-week efficacy analysis of its Phase 3 ORIGIN 3 trial for primary IgA nephropathy (IgAN).
- 2026-09-15 Vera Stock Slides Despite Positive Phase 3 Results Vera Therapeutics (NASDAQ:VERA) stock is down 2% to trade at $33.34, reversing earlier gains after disclosing positive late-stage ORIGIN 3 trial results for the company''s TRUTAKNA drug.
- 2026-09-15 Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR, Prevented IgAN Disease Progression Through 2 Years in ORIGIN 3 Final Analysis
- 2026-09-04 Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).
- 2026-09-01 Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company''s management team will present and participate in one-on-one meetings at upcoming investor conferences.
- 2026-08-17 Vera Therapeutics: FDA''s eGFR Analysis Supports A Speculative Buy Vera Therapeutics is upgraded to Buy following TRUTAKNA''s FDA approval and encouraging eGFR data. The FDA''s exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka''s VOYXACT and Vertex''s povetacicept but enjoys a commercial head start and broad label.
- 2026-08-12 E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA E. Ohman J or Asset Management AB grew its holdings in Vera Therapeutics, Inc. (NASDAQ: VERA) by 99.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,777 shares of the company''s stock after purchasing an additional 42,787 shares during